These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17980884)

  • 1. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
    Gouni-Berthold I; Berthold HK; Gylling H; Hallikainen M; Giannakidou E; Stier S; Ko Y; Patel D; Soutar AK; Seedorf U; Mantzoros CS; Plat J; Krone W
    Atherosclerosis; 2008 May; 198(1):198-207. PubMed ID: 17980884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
    Berthold HK; Seidah NG; Benjannet S; Gouni-Berthold I
    PLoS One; 2013; 8(3):e60095. PubMed ID: 23544125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.
    Lakoski SG; Xu F; Vega GL; Grundy SM; Chandalia M; Lam C; Lowe RS; Stepanavage ME; Musliner TA; Cohen JC; Hobbs HH
    J Clin Endocrinol Metab; 2010 Feb; 95(2):800-9. PubMed ID: 19965915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
    Telford DE; Sutherland BG; Edwards JY; Andrews JD; Barrett PH; Huff MW
    J Lipid Res; 2007 Mar; 48(3):699-708. PubMed ID: 17130282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.
    Berthold HK; Naini A; Di Mauro S; Hallikainen M; Gylling H; Krone W; Gouni-Berthold I
    Drug Saf; 2006; 29(8):703-12. PubMed ID: 16872244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.
    Ness GC; Holland RC; Lopez D
    Exp Biol Med (Maywood); 2006 May; 231(5):559-65. PubMed ID: 16636304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
    Liu PY; Liu YW; Lin LJ; Chen JH; Liao JK
    Circulation; 2009 Jan; 119(1):131-8. PubMed ID: 19075102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
    Fazio S
    Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.
    Drouin-Chartier JP; Tremblay AJ; Lemelin V; Lépine MC; Lamarche B; Couture P
    Diabetes Obes Metab; 2016 Dec; 18(12):1226-1235. PubMed ID: 27460541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies.
    Kasmas SH; Izar MC; França CN; Ramos SC; Moreira FT; Helfenstein T; Moreno RA; Borges NC; Figueiredo-Neto AM; Fonseca FA
    Braz J Med Biol Res; 2012 Nov; 45(11):1095-101. PubMed ID: 22801416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
    Assmann G; Kannenberg F; Ramey DR; Musliner TA; Gutkin SW; Veltri EP
    Curr Med Res Opin; 2008 Jan; 24(1):249-59. PubMed ID: 18053317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
    JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.